14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$0.57 (0.37%)

Volume: 69.82k

Closed: Sep 30, 2022

Hollow Logo Score: -2.097

eFFECTOR Therapeutics, Inc. Stock Forecast

$0.57 (0.37%)

Volume: 69.82k

Closed: Sep 30, 2022

Score Hollow Logo -2.097
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSI min/max Values: [ 20 - 75 ] RSI14 is 35 and the stock is currently not being overbought or oversold
Last Reaction
Be the first to comment on EFTR

Green day on Friday for eFFECTOR Therapeutics, Inc.
(Updated on Sep 30, 2022)


Sell candidate since 2022-09-19 Loss -3.03% PDF

The eFFECTOR Therapeutics, Inc. stock price gained 0.37% on the last trading day (Friday, 30th Sep 2022), rising from $0.57 to $0.57. During the last trading day the stock fluctuated 7.22% from a day low at $0.55 to a day high of $0.59. The price has been going up and down for this period, and there has been a -6.17% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 4 thousand more shares were traded than the day before. In total, 70 thousand shares were bought and sold for approximately $39.94 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -51.86% during the next 3 months and, with a 90% probability hold a price between $0.13 and $0.34 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, September 02, 2022, and so far it has risen 15.30%. Further rise is indicated until a new top pivot has been found. eFFECTOR Therapeutics, Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. The very low volume increases the risk and reduces the other technical signals issued. Some negative signals were issued as well, and these may have some influence on the near short-term development. The eFFECTOR Therapeutics, Inc. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.61. On a fall, the stock will find some support from the short-term average at $0.57. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

eFFECTOR Therapeutics, Inc. finds support from accumulated volume at $0.56 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0397 between high and low, or 7.22%. For the last week, the stock has had daily average volatility of 9.11%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations For The Upcoming Trading Day Of Monday 3rd

For the upcoming trading day on Monday, 3rd we expect eFFECTOR Therapeutics, Inc. to open at $0.57, and during the day (based on 14 day Average True Range), to move between $0.50 and $0.64, which gives a possible trading interval of +/-$0.0683 (+/-11.93%) up or down from last closing price. If eFFECTOR Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 23.87% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.56 (1.70%) than the resistance at $0.63 (10.12%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is eFFECTOR Therapeutics, Inc. stock A Buy?

eFFECTOR Therapeutics, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -2.097

Sell Candidate Unchanged

Predicted Opening Price for eFFECTOR Therapeutics, Inc. of Monday, October 3, 2022

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Fair opening price October 3, 2022 Current price
$0.57 $0.57 (Overvalued)

Remember To Visit Our YouTube Channel

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.61 6.69 %
0.60 4.04 %
0.59 2.40 %
Current price: 0.57
Support 0.56 -2.90 %
0.55 -4.54 %
0.53 -7.19 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.70 22.46 %
0.65 13.97 %
0.63 10.12 %
Current price 0.57
Support 0.56 -1.70%
0.54 -5.61%
0.50 -13.27%

Click to get the best stock tips daily for free!

Hot Stocks To Watch:

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 676 stocks, only a few dozen will trigger such a signal!

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit euk... EFTR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT